CYP2C19 and breast cancer: To obtain a more clinically relevant measure of protein expression levels, we randomly selected clinical paraffin-embedded tumor samples representative of all the breast cancer subtypes and subjected them to IHC analysis against CYP2C19/9, CYP2J2, CYP3A4 and sEH antibodies.